Abstract
The enzyme human steroid 5-α reductase type II (SRD5A2) and androgen receptor (AR) are critical mediators of androgen action, suggesting a potential role in hormonally related cancers. The SRD5A2 gene harbours two frequent polymorphic sites, one in the coding region, at codon 89 of exon 1, where valine is substituted by leucine (V89L) and the other in the 3′ untranslated region (3′ UTR) where a variable number of dinucleotide TA repeat lengths exists. The V89L polymorphism is known to alter the activity of this enzyme. In the present study we examined 144 sporadic breast tumours from Italian patients for the V89L and TA polymorphisms by sequence and fragment analysis, respectively. Tumour extract prostate specific antigen (PSA) concentration as well as a number of well-established clinical and pathological parameters were evaluated. The results show that 53% of the tumours were homozygous for VV alleles, 37% were heterozygous for VL alleles and 10% were homozygous for LL alleles. TA(0) repeats were found in tumours with VV, LL and VL genotypes. TA(9) repeats were only found in VV homozygotes and were totally absent from either LL homozygotes or VL heterozygotes. PSA expression was significantly elevated in tumours with VV genotype. The presence of LL alleles in breast tumours is associated with earlier onset and shorter disease-free (RR = 2.65; P = 0.013) and overall survival (RR = 3.06; P = 0.014) rates. The VV genotype is associated with a more favourable prognosis. Our study suggests that the polymorphism in codon 89 of exon 1 of the human 5α-reductase gene is related with TA repeat genotypes, PSA expression and breast cancer prognosis. More specifically, we found that the LL genotype is also associated with earlier onset and more aggressive forms of breast cancer. Long-term-outcome studies are needed to investigate the relevance of this polymorphism to breast cancer susceptibility. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Akalu A, Dimajian DA, Highshaw RA, Nichols PW and Reichardt JK (1999) Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5-alpha reductase during prostate cancer progression. J Urol 161: 1355–1358
Alexiera-Figusch J, van Putten WLS, Blankestein MA, Blonk-Van Der wijst J and Klijn JGM (1988) The prognostic value and relationships of patient characteristics, estrogen and progestin receptors and site of relapse in primary breast cancer. Cancer 61: 758–768
Ardavanis A, Gerakini F, Amanatidou A, Scorilas A, Pateras C, Garoufali A and Pissakas G (1997) Relationships between cathepsin D, PS2 protein and hormonal receptors in breast cancer cytosols: Inconsistency with their established prognostic significance. Anticancer Res 17: 3665–3670
Balbin M and Lopez-Otin C (1996) Hormonal regulation of the human pepsinogen C gene in breast cancer cells: Identification of a cis-acting element mediating its induction by androgens, glucocorticoids and progesterone. J Biol Chem 271: 15175–15181
Bertuzzi A, Daidone MG, Di Fronzo G and Silvestrini R (1981) Urinary androgens and tumor estrogen receptor as predictors of ovariectomy response and of survival in advanced breast cancer. Breast Cancer Res Treat 1: 201–205
Bharaj B, Vassilikos EJK and Diamandis EP (1999) Rapid and accurate determination of CAG repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. Clin Biochem 32: 327–332
Bharaj BS, Angelopoulou K and Diamandis EP (1998) Rapid sequencing of the p53 gene with a new automated sequencer. Clin Chem 44: 1397–1403
Bharaj BS, Scorilas A, Maurizia G and Diamandis EP (2000) TA repeat polymorphism of the 5alpha-reductase gene and breast cancer. Cancer Epidemiology, Biomarkers and Prevention 9 (4): 387–393
Bloom HJG and Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–377
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH and Morgan FJ (1984) Androgen receptors in breast cancer. Cancer 54: 2436–2440
Coffey DS (1993) Prostate cancer. An overview of an increasing dilemma. Cancer 71: 880–886
Dressler LG, Seamer LC, Owens MA, Clark GM and McGuire WL (1988) DNA flow cytometry and prognostic factors in 1131 frozen breast cancer specimens. Cancer 61: 420–427
Ferguson RA, Yu H, Kalyvas M, Zammit S and Diamandis EP (1996) Ultrasensitive detection of prostate specific antigen by a new time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. Clin Chem 42: 675–684
Foekens JA, van Putten WLJ and Portegen H (1993) Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: Multivariate analysis. J Clin Oncol 11: 899–908
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD and Andriole GL (1992) The effect of finesteride in men with benign prostate hyperplasia. N Eng J Med 327: 1185–1191
Grattarola R (1973) Androgens in breast cancer. A typical endometrial hyperplasia and breast cancer in married pre-menopausal women. Am J Obstet Gynecol 116: 423–428
Grattarola R, Secreto G, Recchione C and Castellini W (1974) Androgens in breast cancer. II Endrometrial adenocarcinoma and breast cancer in married post menopausal women. Am J Obstet Gynecol 118: 173–181
Griniatsos J, Diamandis E, Gioti J, Karyda I, Vassilopoulos PP and Agnanti N (1998) Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer. Anticancer Res 18: 683–688
Hahnel R and Hahnel E (1996) Expression of the PIP/GCDFP-15 gene and survival in breast cancer. Virchows Arch 429: 365–369
Hall RE, Clements JA, Birrell SN and Tilley WD (1998) Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumors. Br J Cancer 78: 360–365
Hill P, Garbaczewski L and Wynder EL (1983) Testosterone in breast fluid. Lancet 1: 761
Kantoff PW, Febbo PG, Giovannucci E, Krithivas K, Dahl DM, Chang G, Hennekens CH and Brown M (1997) A polymorphism of the 5-alpha reductase gene and its association with prostate cancer: A case control analysis. Cancer Epidemiol Biomarkers Prev 6: 189–192
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Key TJA and Pike MC (1988) The role of estrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24: 29–43
Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG and Henzen-Logmans SC (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32: 1560–1565
Labrie F, Sugimoto Y, Luu-The, Simard J, Lachance Y, Bachvarov D and LeBlanc G (1992) Structure of human type II 5 Alpha reductase gene. Endocrinology 131: 1571–1573
Lopez-Otin C and Diamandis EP (1998) Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 19: 365–396
Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with folin-phenol reagent. J Biol Chem 193: 265–275
Magklara A, Scorilas A, Catalona WJ and Diamandis EP (1999) The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45: 1960–1966
Magklara A, Scorilas A, Stephan C, Kristiansen G, Hauptmann S, Jung K and Diamandis EP (2000) Down-regulation of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant vs non-malignant prostatic tissue. Urology 56: 527–532
Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN and Shi CY (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 57: 1020–1022
Makridakis N, Di Salle E and Reichardt JK (2000) Biochemical and pharmacogenetic dissection of human steroid 5alpha-reductase type II. Pharmacogenetics 10: 407–413
Pisani P, Parkin DM, Bray F and Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18–29
Recchione C, Venturelli E, Manzari A, Cavalleri A and Martinetti A and Secreto G (1995) Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol 56: 541–546
Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC and Ross RK (1995) Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 55: 3973–3975
Reiher A, Kolb R, Reiner G, Jakesz R, Schemper M and Spona J (1987) Prognostic significance of steroid hormone receptor and histopathological characterization of human breast cancer. J Cancer Res Clin Oncol 113: 285–290
Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC and Henderson BE (1992) 5 alpha reductase activity and risk of prostate cancer among Japanese and US whites and black males. Lancet 339: 887–889
Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 51: 660–672
Scorilas A, Diamandis EP, Levesque MA, Diamandi A, Khosravi MJ, Giai M and Ponzone R (1999a) Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: An independent favorable prognostic factor in node-positive patients. Clin Cancer Res 5: 1778–1785
Scorilas A, Trangas T, Yotis J, Pateras C and Talieri M (1999b) Determination of c-myc amplification and overexpression in breast cancer patients. Evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathologic characteristics using univariate and multivariate analysis. Br J Cancer 81: 1385–1391
Scorilas A, Yu H, Soosaipilai A, Gregorakis A and Diamandis EP (2000a) Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clin Chim Acta 292: 127–138
Scorilas A, Talieri M, Ardavanis A, Courtis N, Yotis J, Dimitriadis E, Tsiapalis C and Trangas T (2000b) Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. Cancer Res 60: 5427–5433
Secreto G and Zumoff B (1983) Pradoxical effects associated with supra-normal urinary testosterone excretion in pre-menopausal women with breast cancer: increased risk of post mastectomy recurrence and higher remission rate after ovariectomy. Cancer Res 43: 3408–3411
Secreto G, Fariselli G, Bandieramonte G, Recchione C, Dati V and Di Pietro S (1983) Androgen excretion in women with a family history of breast cancer or with epithelial hyperplasia or cancer of the breast. Eur J Cancer Clin Oncol 19: 5–10
Secreto G, Venturelli E, Bucci A, Piromalli D, Fariselli G and Galante E (1996) Intratumor amount of sex steroids in elderly breast cancer patients. An approach to the biological characterization of mammary tumors in the elderly. J Steroid Biochem Mol Biol 58: 557–561
Soreide JA, Lea OA, Varhaug JE, Skarstein A and Kvinnsland S (1992) Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlation to prognostic factors and the predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18: 112–118
Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH and Wagner G (1989) Illustrated guide to the TNM/pTNM classification of malignant tumors. TNM atlas, Berlin; New York, Springer-Verlag 343
Stoll BA and Secreto G (1992) New hormone related markers of high risk to breast cancer. Ann Oncol 3: 435–438
Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F and Heuson JC (1996) Aromatase, 17-betahydroxysteroid dehydrogenase and intratissular concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 22: 515–525
Vilchis F, Hernandez D, Canto P, Mendez JP and Chavez B (1997) Codon 89 polymorphism of the human 5-alpha steroid reductase type II gene. Clin Genet 51: 399–402
Vizoso F, Sanchez LM, Diez-Itza I, Merino AM and Lopez-Otin C (1995) Pepsinogen C is a new prognostic marker in primary breast cancer. J Clin Oncol 13: 54–61
Wigley CW, Prihoda JS, Mowszowicz I, Mendonca BB, New MI, Wilson JD and Russell DW (1994) Natural mutagenesis study of human steroid 5-alpha reductase 2 isozyme. Biochemistry 33: 1265–1270
Wilson JD, Griffin JE and Russell D (1993) Steroid 5-alpha-reductase 2 defiency. Endocr Rev 14: 577–593
Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque M and Roagna R (1995) Prostate specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104–2110
Yu H, Diamandis EP, Levesque MA, Giai M, Roagna R and Ponzone R (1996) Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40: 171–178
Yu H, Levesque MA, Clark GM and Diamandis EP (1998) Prognostic value of prostate specific antigen for women with breast cancer; a large United States cohort study. Clin Can Res 4: 1489–1487
Zarghami N, Grass L and Diamandis EP (1997) Steroid hormone regulation of prostate specific antigen gene expression in breast cancer. Br J Cancer 75: 579–588
Zubiaga AM, Belasco JG and Greenberg ME (1995) The nanomer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol Cell Biol 15: 2219–2230
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Scorilas, A., Bharaj, B., Giai, M. et al. Codon 89 polymorphism in the human 5α-reductase gene in primary breast cancer. Br J Cancer 84, 760–767 (2001). https://doi.org/10.1054/bjoc.2000.1681
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1681
Keywords
This article is cited by
-
Activity and expression of progesterone metabolizing 5α-reductase, 20α-hydroxysteroid oxidoreductase and 3α(β)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells
BMC Cancer (2003)
-
A49T, V89L and TA repeat polymorphisms of steroid 5α-reductase type II and breast cancer risk in Japanese women
Breast Cancer Research (2002)